Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III t... Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Mehr anzeigen
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30...
RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...
Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a...
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Can-Fite...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -4.34782608696 | 1.61 | 1.64 | 1.5256 | 74324 | 1.57292431 | CS |
| 4 | 0.11 | 7.69230769231 | 1.43 | 1.84 | 1.43 | 117531 | 1.63041185 | CS |
| 12 | -0.75 | -32.7510917031 | 2.29 | 2.5 | 1.29 | 475537 | 1.61777956 | CS |
| 26 | -3.01 | -66.1538461538 | 4.55 | 4.69 | 1.29 | 268687 | 1.83321161 | CS |
| 52 | -0.39 | -20.207253886 | 1.93 | 4.69 | 1.29 | 159457 | 1.99069077 | CS |
| 156 | -10.36 | -87.0588235294 | 11.9 | 12.9 | 1.29 | 145169 | 5.95735061 | CS |
| 260 | -26.46 | -94.5 | 28 | 43.9 | 1.29 | 699456 | 20.07302158 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| FOXOFOXO Technologies Inc | US$ 0,2753 (22,36%) | 104,79M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 35,15 (4,33%) | 52,24M |
| SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 16,90 (-4,25%) | 46,64M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,21 (4,00%) | 44,89M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,69 (-1,56%) | 44,66M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
